Mechanistic Convergence of the TIGIT and PD-1 Inhibitory Pathways Necessitates Co-Blockade to Optimize Anti-Tumor CD8⁺ T Cell Responses

Although PD-1 and TIGIT are thought to regulate different costimulatory receptors, effectiveness of PD-1 or TIGIT inhibition in preclinical tumor models was reduced in the absence of CD226.